Core Viewpoint - The company, Nuo Cheng Jian Hua, is expected to achieve a net profit of approximately 633 million yuan in 2025, marking a significant increase of around 1.074 billion yuan compared to the previous year, indicating a turnaround from losses to profits in 2025 [1] Group 1: Revenue Growth - The company's pharmaceutical revenue is experiencing rapid growth, driven by the approval of new indications for its drug, Acalabrutinib, for the first-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adult patients [1] - Acalabrutinib has three indications included in the national medical insurance directory, enhancing its market potential [1] - In May 2025, the company received NMPA approval for the marketing application of Tanshinone combined with Lenalidomide for adult patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) who are unsuitable for ASCT [1] Group 2: Business Development - Business development (BD) revenue growth is another key factor contributing to the rapid increase in total revenue for 2025 [1] - The company is advancing its globalization efforts, achieving two BD transactions throughout the year [1] - In January 2025, the company entered into a licensing collaboration with Prolium Bioscience Inc. regarding the CD20×CD3 bispecific antibody ICP-B02 (CM355) [1] - In October 2025, the company reached a licensing agreement with Zenas BioPharma, Inc. concerning Acalabrutinib and two preclinical molecular-related rights [1]

Earnings Forecasts - Shengyi Electronics expects a net profit of 1.431 billion to 1.513 billion yuan in 2025, an increase of 331.03% to 355.88% year-on-year [1] - Tigermed anticipates a net profit of 830 million to 1.23 billion yuan in 2025, representing a growth of 105% to 204% year-on-year [2] - Shunbo Alloy forecasts a net profit of 210 million to 270 million yuan in 2025, with an increase of 222.96% to 315.23% year-on-year [3] - Jinkong Electric expects a net profit of 155 million to 195 million yuan in 2025, reflecting a growth of 383.21% to 507.9% year-on-year [9] - Baiao Saitu anticipates a net profit of 162 million to 182 million yuan in 2025, with a year-on-year increase of 384.26% to 443.88% [18] - Panjiang Co. expects a net profit of 318 million to 380 million yuan in 2025, representing a growth of 205.30% to 264.83% year-on-year [38] Loss Forecasts - Liaoning Energy predicts a net loss of 273 million to 410 million yuan in 2025, compared to a profit of 202 million yuan in the previous year [5] - Anbotong anticipates a net loss of 114 million to 165 million yuan in 2025, with a revenue decrease of 19.65% to 27.25% [7] - Wantai Bio forecasts a net loss of 330 million to 410 million yuan in 2025, compared to a profit of 106 million yuan in the previous year [12] - Xingyun Co. expects a net loss of 155 million to 230 million yuan in 2025, compared to a loss of 82.44 million yuan in the previous year [20] - Huaxing Co. anticipates a net loss of 800 million to 1.2 billion yuan in 2025, with a reduction in loss compared to 1.67 billion yuan in the previous year [46] New Product Approvals - Hengrui Medicine received acceptance for a new indication application for its innovative drug, combining Carrelizumab and Apatinib for treating unresectable liver cancer [4] - Tianen Kang's subsidiary received a drug registration acceptance notice for Lidocaine and Prilocaine aerosol [31] - Lisheng Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs [40] Share Buyback Plans - Hengyuan Coal Power plans to repurchase shares with a total amount not less than 200 million yuan and not exceeding 250 million yuan [13] Contract Wins - China Communication Signal Co. won contracts totaling approximately 5.26 billion yuan for 21 important projects in the railway and urban rail transit markets [37]

诺诚健华(09969.HK)发布公告，于2025年1月1日至2025年12月31日。经财务部门初步测算，公司预计 2025年实现营业总收入人民币23.65亿元左右，与上年同期相比增长134%左右。公司预计2025年度首次 实现扭亏为盈。归属于母公司所有者的净利润为人民币6.33亿元左右，比上年同期归属于母公司所有者 的净利润增加人民币10.74亿元左右。公司预计2025年度归属于母公司所有者扣除非经常性损益后的净 利润为人民币5.34亿元左右，比上年同期增加人民币9.74亿元左右。 诺诚健华港股市值174.33亿港元，在生物制品Ⅱ行业中排名第9。主要指标见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年1月29日收盘，诺诚健华(09969.HK)报收于11.62港元，下跌0.43%，成交量357.89万股，成交 额4154.0万港元。投行对该股的评级以买入为主，近90天内共有3家投行给出买入评级，近90天的目标 均价为17.9港元。国元国际控股最新一份研报给予诺诚健华买入评级，目标价16.81港元。 机构评级详 ...

（原标题：诺诚健华(09969)预计2025年度归母净利润约6.33亿元 首次实现扭亏为盈） 智通财经APP讯，诺诚健华(09969)发布公告，于2025年1月1日至2025年12月31日。经财务部门初步测 算，公司预计2025年实现营业总收入人民币23.65亿元左右，与上年同期相比增长134%左右。公司预计 2025年度首次实现扭亏为盈。归属于母公司所有者的净利润为人民币6.33亿元左右，比上年同期归属于 母公司所有者的净利润增加人民币10.74亿元左右。公司预计2025年度归属于母公司所有者扣除非经常 性损益后的净利润为人民币5.34亿元左右，比上年同期增加人民币9.74亿元左右。 与上年相比，2025年业绩变化的主要原因如下： (一)本年度公司药品收入持续快速增长。2025年4月，奥布替尼获批新适应症，用于一线治疗慢性淋巴 细胞白血病(CLL) ╱小淋巴细胞淋巴瘤(SLL)成人患者。此前，奥布替尼有三项获批适应症：既往至少 接受过一种治疗的成人慢性淋巴细胞白血病(CLL) ╱小淋巴细胞淋巴瘤 (SLL)患者(复发难治 CLL/SLL)，既往至少接受过一种治疗的成人套细胞淋巴瘤(MCL)患者(复发难治MC ...

格隆汇1月29日丨诺诚健华(688428.SH)公布，经财务部门初步测算，公司预计2025年实现营业总收入人 民币23.65亿元左右，与上年同期相比增长134%左右。公司预计2025年度首次实现扭亏为盈。归属于母 公司所有者的净利润为6.33亿元左右，比去年同期归属于母公司所有者的净利润增加10.74亿元左右。公 司预计2025年度归属于母公司所有者扣除非经常性损益后的净利润5.34亿元左右，比上年同期增加9.74 亿元左右。 本年度公司药品收入持续快速增长。2025年4月，奥布替尼获批新适应症，用于一线治疗慢性淋巴细胞 白血病（CLL）/小淋巴细胞淋巴瘤（SLL）成人患者。此前，奥布替尼有三项适应症：既往至少接受过 一种治疗的成人慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）患者（r/rCLL/SLL）,既往至 少接受过一种治疗的成人套细胞淋巴瘤（MCL）患者（r/rMCL）及既往至少接受过一种治疗的成人边 缘区淋巴瘤（MZL）患者（r/rMZL）均纳入国家医保目录，其中奥布替尼为中国首个且唯一获批针对 MZL适应症的BTK抑制剂；除奥布替尼外，2025年5月，坦昔妥单抗联合来那度胺治疗不适合AS ...

InnoCare Pharma Limited 諾誠健華醫藥有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不意圖構成或構成收購、購買或認購本公司任何證券之邀請、要約或其 一部分。 – 1 – 一、本期未經審計的業績預告情況 本公告乃由諾誠健華醫藥有限公司（「本公司」，連同其附屬公司統稱「本集團」） 根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則（「上市規則」）第13.09(2)條及第 13.10B條及香港法例第571章證券及期貨條例第XIVA部的內幕消息條文（定義見 上市規則）作出。 本公司董事會及全體董事保證，本公告內容不存在任何虛假、誤導性陳述或重 大遺漏，並對其內容的真實性、準確性及完整性承擔責任。 本公告所載的主要財務數據及指標乃根據中國公認會計準則編製的初步數據， 未經本公司核數師審計。 （股份代號：9969） （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） 有關20 ...

| A | 股代码：688428 | 股简称：诺诚健华 A | 公告编号：2026-001 | | --- | --- | --- | --- | | 港股代码：09969 | | 港股简称：诺诚健华 | | 诺诚健华医药有限公司 （二）业绩预告情况 （1）经财务部门初步测算，诺诚健华医药有限公司（以下简称"公司"） 预计 2025 年实现营业总收入人民币 23.65 亿元左右，与上年同期相比增长 134% 左右。 （2）公司预计 2025 年度首次实现扭亏为盈。归属于母公司所有者的净利润 为6.33亿元左右，比去年同期归属于母公司所有者的净利润增加10.74亿元左右。 （3）公司预计 2025 年度归属于母公司所有者扣除非经常性损益后的净利润 5.34 亿元左右，比上年同期增加 9.74 亿元左右。 （三）本次业绩预告未经注册会计师审计。 二、 上年同期经营业绩和财务状况 一、 本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300436 | 广生堂 | 105.01 | 14.00% | 21.58万 | | 22.03亿 | | 300765 | 新诺威 | 46.21 | 12.90% | 23.06万 | | 10.27亿 | | 688428 | 诺诚健华 | 20.39 | 2.05% | 6.96万 | | 1.41亿 | | 300401 | 化园生物 | 17.71 | 1.84% | P 29.42万 | | 5.24亿 | | 688192 | 迪哲医药 | 58.96 | 1.78% | 2.60万 | | 1.52亿 | | 002099 | 海翔药业 | 6.35 | 1.28% | 33.69万 | | 2.14亿 | | 688578 | 文力斯 | 101.30 | 1.25% | 4.40万 | | 4.40 乙 | | 300573 | 兴齐眼药 | 72.10 | 1.22% | 8.25万 | | 5.96亿 | ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company is entering a new drug approval harvest period with a well-structured pipeline covering ADC (Antibody-Drug Conjugates) and IO (Immuno-Oncology) [3][10]. - The company has multiple oncology product pipelines, including immune therapy, ADC targeted therapy, and oncolytic virus drugs, with several candidates in clinical stages [3][11]. - The company achieved its first profitability and positive operating cash flow in the first half of 2025, driven by business development and sales [3][25]. Summary by Sections R&D Coverage and Pipeline - The company focuses on oncology treatment, establishing a comprehensive ADC technology platform and has developed multiple ADC products, including PD-1 monoclonal antibody and MRG003 [11][14]. - The pipeline includes six ADC drugs, one oncolytic virus, and one TCE (T-cell Engager) drug in clinical stages, with several candidates entering pivotal trials [14][18]. Unique Features of ADC Candidates - MRG003 (EGFR ADC) has been approved for NPC (Nasopharyngeal Carcinoma) in China, showing superior survival benefits and safety compared to competitors [4][30]. - MRG004A (TF-ADC) is in Phase III trials for pancreatic cancer, while MRG006A (GPC3 ADC) targets the liver cancer market and is expected to enter Phase III trials in 2026 [6][30]. Oncolytic Virus and International Expansion - The company introduced the oncolytic virus therapy CG0070, which is in critical registration trials in China and has shown promising efficacy in the U.S. for bladder cancer [5][30]. - The company has successfully partnered for international expansion with MRG007 (CDH17 ADC) and CTM012 (CD3/4-1BB/DLL3 tri-antibody) [5][30]. Financial Projections and Investment Recommendations - Revenue projections for 2025, 2026, and 2027 are estimated at 880 million, 1.02 billion, and 1.49 billion yuan, respectively, with expected growth rates of 138%, 16%, and 47% [6][30]. - The company is still in the investment phase for innovative drug development, with projected net profits of -20 million, 10 million, and 280 million yuan for the same years [6][30].

Group 1 - The core viewpoint of the news is that Nocera Biopharma experienced a decline in stock price and significant trading activity, indicating high investor interest and potential volatility in the stock [1] - On January 26, Nocera Biopharma's stock fell by 2.02%, with a trading volume of 186 million yuan. The net financing purchase was 2.6452 million yuan, with a total financing and securities balance of 409 million yuan [1] - The financing balance of Nocera Biopharma is 408 million yuan, accounting for 7.66% of its market capitalization, which is above the 90th percentile of the past year, indicating a high level of leverage [1] Group 2 - Nocera Biopharma, established on November 3, 2015, focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [2] - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and minimal contributions from testing and research services [2] - For the period from January to September 2025, Nocera Biopharma reported a revenue of 1.115 billion yuan, a year-on-year increase of 59.85%, while the net profit attributable to shareholders was -64.415 million yuan, reflecting a 76.61% year-on-year increase in losses [2] Group 3 - As of September 30, 2025, the top ten circulating shareholders of Nocera Biopharma include several new entrants, such as Wan Jia You Xuan and Ping An Medical Health, while some existing shareholders have reduced their holdings [3] - The sixth-largest shareholder, Fuguo Precision Medical Flexible Allocation Mixed A, decreased its holdings by 427,100 shares, while new shareholders have entered the top ten list [3]